Trial Profile
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms RECOGNISE
- Sponsors AstraZeneca
- 18 Aug 2020 Status changed from recruiting to completed.
- 18 Jun 2019 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.
- 18 Jun 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.